Broccoli tegen huidziekte?*
Uit een studie met muizen blijkt dat de bioactieve stof sulforafaan goed helpt tegen de huidziekte Epidermolysis Bullosa Simplex (EBS). Sulforafaan is een
isothiocyanaat en wordt overvloedig gevonden in broccoli. Speciale muizen met een ernstige vorm van EBS gingen normaal binnen 3 dagen dood echter met een plaatselijke behandeling met een oplossing met sulforafaan bleken na 4 dagen nog 85% van de muizen te leven en hadden
ze ook geen enkele blaar. EBS ontstaat doordat functies van bepaalde eiwitten,de keratinen gestoord zijn. Het lijkt erop dat sulforafaan de aanmaak van nieuwe keratinen bevordert. De onderzoekers gaan nu verder met onderzoek bij mensen.
Skin Blistering Disease EBS Treated With Natural Chemical Found In Broccoli
Johns Hopkins scientists have found yet another reason why you should listen to your mother when she tells you to eat your vegetables. Sulforaphane, a chemical present at high levels in a precursor form in broccoli and related veggies (cauliflower, Brussels sprouts, etc.), helps prevent the severe blistering and skin breakage brought on by the rare and potentially fatal genetic disease epidermolysis bullosa simplex
(EBS).
The researchers treated newborn mice with a severe form of EBS -- so bad they all died within three days -- with a topical solution containing sulforaphane and found marked improvement; after four days more than 85 percent of the treated mice were alive and blister-free. These findings appear online in Proceedings of the National Academy of
Sciences.
The basis of EBS, notes study author Pierre Coulombe, Ph.D., professor of biological chemistry, lies in two specific genes that make proteins known as keratins. Normally, the keratins join together and form highly resilient fibers in the lower portion of skin, helping make it durable. If either keratin is defective, they don't mesh and the lower skin tissue becomes unusually fragile and gets damaged from the mildest mechanical stress -- leading to blistering pain, a higher risk of infection, and in the most severe cases, death.
"Humans have around 54 distinct keratins, many of which are similar in structure and function," says Coulombe. "We figured we might be able to exploit this similarity and dial up a replacement by triggering the activation of a suitable signaling pathway in skin." He predicted that sulforaphane might stimulate the formation of a surrogate skin-strengthening keratin to stand in for the defective
one.
The desire to learn more about sulforaphane led Coulombe and his co-workers to Paul Talalay, M.D., professor of pharmacology who had previously identified sulforaphane as a cancer-preventive agent. "It turns out that treatment with low doses of sulforaphane triggers the expression of selected keratin genes in skin," says Coulombe. "So we began what evolved into a highly rewarding collaboration and found it does indeed work in a mouse model for EBS."
"This is the first suggestion that we may be able to treat this terrible disease," adds Talalay, a co-author of this study. "And we didn't need to invent a new drug; sulforaphane is naturally found in our
diet."
The team will next test whether sulforaphane can stimulate the proper keratin protein in the appropriate subset of human skin cells -- a vital matter for any future medical hopes. Beyond that are issues of how effective a topical application would be on human skin, which is considerably thicker than mouse skin, as well as examining the long term effects of sulforaphane treatment.
"If we can clear these important hurdles, then sulforaphane can potentially be a tremendous therapeutic, with the added benefit of having anticancer properties," Coulombe says. "And when you consider that the only current option for EBS is wrapping gauze around trauma-prone areas to minimize breakage, and otherwise avoiding infection and making sure blisters heal properly, then even a mild success would be a significant benefit for these
patients."
The research was funded by the National Institutes of Health, the March of Dimes Birth Defect Research Foundation, the American Institute for Cancer Research, and the Lewis B. and Dorothy Cullman Foundation.
Authors on the paper are Michelle L. Kerns, Daryle DePianto, Albena T. Dinkova-Kostova, Talalay and Coulombe, all of
Hopkins. (September 2007)
Reacties:
